Scholars Central

Case reportPublished 7 Jan 2026

Ensuring Drug Interchangeability: Key Bioequivalence Principles

Authors: Dr. Marco DeLuca

Department of Clinical Trials, Aurora Institute of Health Sciences, Aurora University, Bellavista, Italy

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Bioequivalence studies are critical for demonstrating drug product interchangeability by assessing pharmacokinetic equivalence. Regulatory agencies provide stringent guidelines, often utilizing dissolution testing and statistical analysis. Advances include novel statistical methods and in vitro data. The Biopharmaceutics Classification System (BCS) may allow for study waivers. Complex drug products and specialized delivery systems require tailored approaches. Pharmacokinetics underpins these assessments, informing interchangeability and post-approval monitoring. Future research focuses on innovation and quality assurance, while food effects remain a relevant design consideration.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Clinical Pharmacology & Biopharmaceutics.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Pharmacology & Biopharmaceutics
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Dr. Marco DeLuca”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels